Idursulfase (idursulfase-IT [HGT-2310])
TAK-609-3001
Phase 3 small_molecule active
Quick answer
Idursulfase (idursulfase-IT [HGT-2310]) for Hunter Syndrome and Cognitive Impairment is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Hunter Syndrome and Cognitive Impairment
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active